Zoetis Secures Conditional FDA Approval for Dectomax®-CA1 in Cattle
Parsippany, NJ – September 30, 2025 – Zoetis Inc. announced that Dectomax®-CA1 Injectable has received conditional approval from the...
AI in Healthcare Alzheimer’s Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy cGxP Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP GMP compliance Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Parsippany, NJ – September 30, 2025 – Zoetis Inc. announced that Dectomax®-CA1 Injectable has received conditional approval from the...
